annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 14B A phase I dose-escalation study of IMGN388 in patients with solid tumors.
(Abstract #3058)
D. S. Thompson, A. Patnaik, J. C. Bendell, K. Papadopoulos, J. R. Infante,
R. A. Mastico, D. Johnson, A. Qin, J. J. O’Leary, A. W. Tolcher
Brd. 14C A phase I study of two different schedules of nab-paclitaxel (Nab-p) with
ascending doses of vandetanib (V) in patients (pts) with advanced solid
tumors. (Abstract #3059)
A. B. El-Khoueiry, S. Iqbal, H. Lenz, L. Roman, B. J. Gitlitz, D. Yang, S. Cole,
J. Shriki, C. Hughlett, A. Garcia
Brd. 14D Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in
combination with letrozole for first-line treatment of patients with
ER-positive, HER2-negative breast cancer. (Abstract #3060)
D. J. Slamon, S. A. Hurvitz, S. Applebaum, J. A. Glaspy, M. K. Allison,
B. A. DiCarlo, R. D. Courtney, S. T. Kim, S. Randolph, R. S. Finn
Brd. 14E Final analysis of a phase I single dose-escalation study of the novel
polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors.
(Abstract #3061)
T. Gil, P. Schöffski, A. Awada, H. Dumez, S. Bartholomeus, J. Selleslach,
M. Taton, H. Fritsch, P. Glomb, G. M. Munzert
Brd. 14F Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736
(PF-736), a selective inhibitor of CHK1 kinase. (Abstract #3062)
N. Brega, G. A. McArthur, C. Britten, S. G. Wong, E. Wang, K. D. Wilner,
A. Blasina, G. K. Schwartz, J. Gallo, A. N. Tse
Brd. 14G Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination
with gemcitabine in advanced solid tumors. (Abstract #3063)
R. Bahleda, A. Spreafico, J. Soria, C. Moldovan, C. Belli, F. Fiorentini, A. Scaburri,
M. A. Pacciarini, B. Laffranchi, M. Reni
Brd. 14H A phase I dose-escalation study of SCH 900776, a selective inhibitor of
checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in
subjects with advanced solid tumors. (Abstract #3064)
A. Daud, G. M. Springett, D. S. Mendelson, P. N. Munster, J. W. Goldman,
J. R. Strosberg, G. Kato, T. Nesheiwat, R. Isaacs, L. S. Rosen
Brd. 15A Phase l study of the oral CDK-TRKA inhibitor PHA-848125 administered with
prolonged schedules of administration. (Abstract #3065)
S. Cresta, C. Sessa, G. Del Conte, A. Locatelli, E. Gallerani, F. Fiorentini,
A. Scaburri, M. A. Pacciarini, R. Alzani, L. Gianni
Brd. 15B Phase I study of danusertib (D) in combination with bevacizumab (B) in solid
tumors. (Abstract #3066)
P. J. Rosen, A. W. Tolcher, P. Lee, M. Smitley, M. Fuerst, R. Spinelli, S. Crippa,
M. G. Jannuzzo, S. Comis, K. Papadopoulos
Brd. 15C A phase I pharmacological and pharmacodynamic study of MK-1775, a
Wee1 tyrosine kinase inhibitor, in monotherapy and combination with
gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
(Abstract #3067)
S. Leijen, J. H. Schellens, G. Shapiro, A. C. Pavlick, R. Tibes, T. Demuth,
J. Viscusi, J. D. Cheng, Y. Xu, A. M. Oza
Brd. 15D Safety and clinical activity of the histone deacetylase inhibitor givinostat in
combination with meclorethamine in relapsed/refractory Hodgkin lymphoma
(HL). (Abstract #3068)
C. Carlo-Stella, A. Guidetti, S. Viviani, V. Bonfante, A. Marchiano, B. Gatti,
C. D’Urzo, M. A. Di Nicola, P. Corradini, A. M. Gianni
Brd. 15E Phase I pharmacokinetic and pharmacodynamic study of the heat shock
protein 90 inhibitor AT13387 in patients with refractory solid tumors.
(Abstract #3069)
G. Shapiro, E. L. Kwak, B. J. Dezube, D. P. Lawrence, J. M. Cleary, S. Lewis,
M. Squires, V. Lock, J. F. Lyons, M. Yule
310